Seminars in Nephrology
Volume 24, Issue 2 , Pages 101-114 , March 2004

Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II1

  • Rajiv Agarwal

      Affiliations

    • Indiana University School of Medicine and Richard L. Roudebush VA Medical Center, Indianapolis, IN, USA
    • Corresponding Author InformationAddress reprint requests to Rajiv Agarwal, MD, Associate Professor of Clinical Medicine, Division of Nephrology, Department of Medicine, Indiana University and RLR VA Medical Center, 1481 West 10th Street, 111N, Indianapolis, IN 46202 USA
    • ,
  • Ruth C Campbell

      Affiliations

    • University of Alabama at Birmingham, Birmingham, AL, USA
    • ,
  • David G Warnock

      Affiliations

    • University of Alabama at Birmingham, Birmingham, AL, USA

References 

  1. Griendling KK, Sorescu D, Lassegue B, et al.  Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2000;20:2175–2183
  2. Nath KA, Ngo EO, Hebbel RP, et al.  alpha-Ketoacids scavenge H2O2 in vitro and in vivo and reduce menadione-induced DNA injury and cytotoxicity. Am J Physiol. 1995;268:C227–C236
  3. Varma SD, Devamanoharan PS. Excretion of hydrogen peroxide in human urine. Free Radic Res. 1990;8:73–78
  4. Bruzzi I, Benigni A, Remuzzi G. Role of increased glomerular protein traffic in the progression of renal failure. Kidney Int Suppl. 1997;62:S29–S31
  5. Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease (Role of additional angiotensin II blockade). Am J Physiol Renal Physiol. 2003;284:F863–F869
  6. Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int. 2000;75(suppl):S7–S14
  7. Haugen E, Nath KA. The involvement of oxidative stress in the progression of renal injury. Blood Purif. 1999;17:58–65
  8. Schnackenberg CG. Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol. 2002;282:R335–R342
  9. Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int. 1998;54:775–784
  10. Hannken T, Schroeder R, Stahl RA, et al.  Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int. 1998;54:1923–1933
  11. Wilcox CS. Reactive oxygen species (Roles in blood pressure and kidney function). Curr Hypertens Rep. 2002;4:160–166
  12. Haugen EN, Croatt AJ, Nath KA. Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int. 2000;58:144–152
  13. Kawada N, Imai E, Karber A, et al.  A mouse model of angiotensin II slow pressor response (Role of oxidative stress). J Am Soc Nephrol. 2002;13:2860–2868
  14. Nishiyama A, Fukui T, Fujisawa Y, et al.  Systemic and regional hemodynamic responses to tempol in angiotensin II-infused hypertensive rats. Hypertension. 2001;37:77–83
  15. Nagase M, Ando K, Nagase T, et al.  Redox-sensitive regulation of lox-1 gene expression in vascular endothelium. Biochem Biophys Res Commun. 2001;281:720–725
  16. Delbosc S, Cristol JP, Descomps B, et al.  Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension. 2002;40:142–147
  17. Diep QN, Amiri F, Touyz RM, et al.  PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002;40:866–871
  18. Virdis A, Neves MF, Amiri F, et al.  Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504–510
  19. Chabrashvili T, Kitiyakara C, Blau J, et al.  Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol. 2003;285:R117–R124
  20. Mervaala EM, Cheng ZJ, Tikkanen I, et al.  Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension. 2001;37:414–418
  21. Wang HD, Xu S, Johns DG, et al.  Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res. 2001;88:947–953
  22. Rugale C, Delbosc S, Cristol JP, et al.  Sodium restriction prevents cardiac hypertrophy and oxidative stress in angiotensin II hypertension. Am J Physiol Heart Circ Physiol. 2003;284:H1744–H1750
  23. Cheng ZJ, Vaskonen T, Tikkanen I, et al.  Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension. 2001;37:433–439
  24. Lerman LO, Nath KA, Rodriguez-Porcel M, et al.  Increased oxidative stress in experimental renovascular hypertension. Hypertension. 2001;37:541–546
  25. Welch WJ, Baumgartl H, Lubbers D, et al.  Renal oxygenation defects in the spontaneously hypertensive rat (Role of AT1 receptors). Kidney Int. 2003;63:202–208
  26. Welch WJ, Mendonca M, Aslam S, et al.  Roles of oxidative stress and AT1 receptors in renal hemodynamics and oxygenation in the post-clipped 2K, 1C kidney. Hypertension. 2003;41:692–696
  27. Welch WJ, Wilcox CS. AT1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR. Kidney Int. 2001;59:1257–1263
  28. Rodriguez-Iturbe B, Quiroz Y, Nava M, et al.  Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol. 2002;282:F191–F201
  29. Quiroz Y, Pons H, Gordon KL, et al.  Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol. 2001;281:F38–F47
  30. Rodriguez-Iturbe B, Pons H, Quiroz Y, et al.  Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int. 2001;59:2222–2232
  31. Rodriguez-Iturbe B, Quiroz Y, Herrera-Acosta J, et al.  The role of immune cells infiltrating the kidney in the pathogenesis of salt-sensitive hypertension. J Hypertens. 2002;20(suppl 3):S9–S14
  32. Bapat S, Post JA, Braam B, et al.  Visualizing tubular lipid peroxidation in intact renal tissue in hypertensive rats. J Am Soc Nephrol. 2002;13:2990–2996
  33. Kitamoto S, Egashira K, Kataoka C, et al.  Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J Hypertens. 2000;18:1795–1800
  34. Chade AR, Rodriguez-Porcel M, Rippentrop SJ, et al.  Angiotensin II AT1 receptor blockade improves renal perfusion in hypercholesterolemia. Am J Hypertens. 2003;16:111–115
  35. Onozato ML, Tojo A, Goto A, et al.  Oxidative stress and nitric oxide synthase in rat diabetic nephropathy (Effects of ACEI and ARB). Kidney Int. 2002;61:186–194
  36. Jones EA, Shahed A, Shoskes DA. Modulation of apoptotic and inflammatory genes by bioflavonoids and angiotensin II inhibition in ureteral obstruction. Urology. 2000;56:346–351
  37. Padi SS, Chopra K. Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity. Pharmacol Res. 2002;45:413–420
  38. Padi SS, Chopra K. Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol. Nephron. 2002;92:685–692
  39. Calo LA, Davis PA, Giacon B, et al.  Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension (Effect of ramipril). J Cardiovasc Pharmacol. 2002;40:625–631
  40. de Cavanagh EM, Piotrkowski B, Basso N, et al.  Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J. 2003;17:1096–1098
  41. Hannken T, Schroeder R, Zahner G, et al.  Reactive oxygen species stimulate p44/42 mitogen-activated protein kinase and induce p27(Kip1) (Role in angiotensin II-mediated hypertrophy of proximal tubular cells). J Am Soc Nephrol. 2000;11:1387–1397
  42. Lodha S, Dani D, Mehta R, et al.  Angiotensin II-induced mesangial cell apoptosis (Role of oxidative stress). Mol Med. 2002;8:830–840
  43. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol. 2002;13:3005–3015
  44. Gloy J, Henger A, Fischer KG, et al.  Angiotensin II modulates cellular functions of podocytes. Kidney Int. 1998;67(suppl):S168–S170
  45. Liu H, Bigler SA, Henegar JR, et al.  Cytochrome P450 2B1 mediates oxidant injury in puromycin-induced nephrotic syndrome. Kidney Int. 2002;62:868–876
  46. Gwinner W, Landmesser U, Brandes RP, et al.  Reactive oxygen species and antioxidant defense in puromycin aminonucleoside glomerulopathy. J Am Soc Nephrol. 1997;8:1722–1731
  47. Djordjevic VB, Cosic V, Pavlovic D, et al.  Does captopril change oxidative stress in puromycin aminonucleoside nephropathy?. Ren Fail. 2000;22:535–544
  48. Lombardi DM, Viswanathan M, Vio CP, et al.  Renal and vascular injury induced by exogenous angiotensin II is AT1 receptor-dependent. Nephron. 2001;87:66–74
  49. Keidar S, Heinrich R, Kaplan M, et al.  Oxidative stress increases the expression of the angiotensin-II receptor type 1 in mouse peritoneal macrophages. J Renin Angiotensin Aldosterone Syst. 2002;3:24–30
  50. Yanagitani Y, Rakugi H, Okamura A, et al.  Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension. 1999;33:335–339
  51. Mazza F, Goodman A, Lombardo G, et al.  Heme oxygenase-1 gene expression attenuates angiotensin II-mediated DNA damage in endothelial cells. Exp Biol Med (Maywood). 2003;228:576–583
  52. Pueyo ME, Gonzalez W, Nicoletti A, et al.  Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol. 2000;20:645–651
  53. Mueller C, Baudler S, Welzel H, et al.  Identification of a novel redox-sensitive gene, Id3, which mediates angiotensin II-induced cell growth. Circulation. 2002;105:2423–2428
  54. Schieffer B, Luchtefeld M, Braun S, et al.  Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res. 2000;87:1195–1201
  55. Higashi Y, Sasaki S, Nakagawa K, et al.  Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med. 2002;346:1954–1962
  56. Minuz P, Patrignani P, Gaino S, et al.  Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation. 2002;106:2800–2805
  57. Wassmann S, Hilgers S, Laufs U, et al.  Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002;22:1208–1212
  58. Annuk M, Zilmer M, Lind L, et al.  Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol. 2001;12:2747–2752
  59. Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients (Role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways). J Hypertens. 2001;19:1245–1254
  60. Quinones-Galvan A, Pucciarelli A, Fratta-Pasini A, et al.  Effective blood pressure treatment improves LDL-cholesterol susceptibility to oxidation in patients with essential hypertension. J Intern Med. 2001;250:322–326
  61. Hussein O, Shneider J, Rosenblat M, et al.  Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation (Studies in hypercholesterolemic and hypertensive patients). J Cardiovasc Pharmacol. 2002;40:28–34
  62. Sadoshima J. Novel AT(1) receptor-independent functions of losartan. Circ Res. 2002;90:754–756
  63. Nunez A, Gomez J, Zalba LR, et al.  Losartan inhibits in vitro platelet activation (Comparison with candesartan and valsartan). J Renin Angiotensin Aldosterone Syst. 2000;1:175–179
  64. Kalinowski L, Matys T, Chabielska E, et al.  Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension. 2002;40:521–527
  65. Schwemmer M, Sommer O, Bassenge E. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling. Cardiovasc Drugs Ther. 2001;15:301–307
  66. Kramer C, Sunkomat J, Witte J, et al.  Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan (Role of the active metabolite EXP3179). Circ Res. 2002;90:770–776
  67. Chlopicki S, Koda M, Chabielska E, et al.  Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition. J Physiol Pharmacol. 2000;51:715–722
  68. Buczko W, Matys T, Pawlak R, et al.  Studies on the antithrombotic action of AT1 receptor antagonists. Med Sci Monit. 2001;7:600–605
  69. Monton M, Jimenez A, Nunez A, et al.  Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol. 2000;35:906–913
  70. Jimenez AM, Monton M, Garcia R, et al.  Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats (Comparison of losartan, candesartan, and valsartan). J Cardiovasc Pharmacol. 2001;37:406–412

PII: S0270-9295(03)00198-0

doi: 10.1016/j.semnephrol.2003.11.008

Seminars in Nephrology
Volume 24, Issue 2 , Pages 101-114 , March 2004

Article Tools